MILPITAS, Calif. -
April 22, 2020 -
PRLog -- Plasminogen Activator Inhibitor-1 (PAI-1), also known as endothelial plasminogen activator inhibitor is a serine protease inhibitor that functions as the principal inhibitor of tissue plasminogen activator (tPA) and urokinase (uPA). PAI-1 is present in a number of tissues & cell types and is associated with various thrombotic and fibrinolytic complications. High level of PAI-1 activity is found in patients suffering from myocardial infarction, hemolytic uremic syndrome or stroke whereas low levels of PAI-1 activity are associated with bleeding disorders. Additionally, PAI-1 is a prognosticator in various cancers. BioVision's Plasminogen Activator Inhibitor-1 Activity Assay Kit is a two-step colorimetric assay. In the first step, samples are incubated with a known amount of tPA thereby allowing PAI-1 and tPA to form an inactive complex. In the second step, the residual free tPA converts plasminogen to plasmin, which in turn hydrolyzes the plasmin chromogenic substrate thereby releasing pNA (chromophore)
. The absorbance of the released pNA is inversely proportional to the PAI-1 activity in the samples. The assay kit is simple, specific and can detect as low as 2 U/ml of PAI-1 activity in samples.
Figures:A. PAI-1 Standard Curve. b. Measurement of PAI-1 Activity in pooled human plasma (citrate treated platelet poor plasma) and EA.hy926 culture medium. All assays were performed following kit protocols.
For more information on this assay kit, visit:
https://www.biovision.com/plasminogen-activator-inhibitor-1-activity-assay-kit-c.html
